THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS*

REFERENCES

• Wrighton S. A., Stevens J. C. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 1992; 22: 1–21
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Human cytochrome P450 enzymes, in Cytochrome P450. P. R. Ortiz de Montellano. 2nd ed., Plenum Press, New York 1995; 473–535
   Google Scholar
• Li A. P., Kaminski D. L., Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995; 104: 1–8
   PubMed Web of Science ®Google Scholar
• Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol. Pathol. 1996; 24: 45–57
   Web of Science ®Google Scholar
• Benet L. Z. Pharmacokinetics, in Goodman and Gilman's: The Pharmacological Basis of Therapeutics. J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, A. G. Gilman. 9th ed., McGraw-Hill, New York 1996; 14
   Google Scholar
• Wang P. P., Beaune P, Kaminsky L. S., Dannan G. A., Kadlubar F. F., Larrey D, Guengerich F. P. Purification and characterization of six cytochrome P450 isozymes from human liver microsomes. Biochemistry 1983; 22: 5375–5383
   PubMed Web of Science ®Google Scholar
• Watkins P. B., Wrighton S. A., Maurel P, Schuetz E. G., Mendez-Picon G, Parker G. A., Guzelian P. S. Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA 1985; 82: 6310–6314
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Martin M. V., Beaune P. H., Kremers P., Wolff T, Waxman D. J. Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 1986; 26: 5051–5060
   Google Scholar
• Molowa D. T., Schuetz E. G., Wrighton S. A., Watkins P. B., Kremers P, Mendez-Picon G, Parker G. A., Guzelian P. S. Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proc. Natl. Acad. Sci. USA 1986; 83: 5311–5315
   PubMed Web of Science ®Google Scholar
• Nelson D. R., Koymans L, Kamataki T, Stegeman J. J., Feyereisen R, Waxman D. J., Waterman M. R., Gotoh O, Coon M. J., Estabrook R. W., Gunsalus I. C., Nebert D. W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42
   PubMedGoogle Scholar
• Beaune P. H., Umbenhauer D. R., Bork R. W., Lloyd R. S., Guengerich F. P. Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. Proc. Natl. Acad. Sci. USA 1986; 83: 8064–8068
   PubMed Web of Science ®Google Scholar
• Kolars J. C., Lown K. S., Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton S. A., Merion R. M., Watkins P. B. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247–259
   PubMedGoogle Scholar
• Shimada T., Yamazaki H, Mimura-Ren M, Inui Y, Guengerich F. P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Mechanism-based inactivation of human liver cytochrome P450 IIIA4 by gestodene. Chem. Res. Toxicol. 1990; 3: 363–371
   PubMed Web of Science ®Google Scholar
• Schuetz E. G., Wrighton S. A., Barwick J. L., Guzelian P. S. Induction of cytochrome P-450 by glucocorticoids in rat liver. I. Evidence. J. Biol. Chem. 1984; 259: 1999–2006
   PubMed Web of Science ®Google Scholar
• Schuetz E. G., Guzelian P. S. Induction of cytochrome P-450 by glucocorticoids in rat liver. II. Evidence that glucocorticoids regulate induction of cytochrome P-450 by a non-classical mechanism. J. Biol. Chem. 1984; 259: 2007–2012
   PubMed Web of Science ®Google Scholar
• Miyata M, Nagata K, Yamazoe Y, Kato R. Transcriptional elements directing a liver-specific expression of P450/6betaA (CYP3A2) gene-encoding testosterone 6beta-hydroxylase. Arch. Biochem. Biophys. 1995; 318: 71–79
   PubMed Web of Science ®Google Scholar
• Quattrochi L. C., Mills A. S., Barwick J. L., Yockey C. B., Guzelian P. S. A novel cis-element in a liver cytochrome P450 3A gene confers synergistic induction by glucocorticoids plus antiglucocorticoids. J. Biol. Chem. 1995; 270: 28,917–28,923
   Google Scholar
• Huss J. M., Wang S. I., Astrom A, McQuiddy P, Kasper C. B. Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif. Proc. Natl. Acad. Sci. USA 1996; 93: 4666–4670
   PubMed Web of Science ®Google Scholar
• Kliewer S. A., Moore J. T., Wade L, Staudinger J. L., Watson M. A., Jones S. A., McKee D. D., Oliver B. B., Willson T. M., Zetterstrom R. H., Perlmann T, Lehmann J. M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998; 92: 73–82
   PubMed Web of Science ®Google Scholar
• Calleja C, Pascussi J. M., Mani J. C., Maurel P, Vilaren M. J. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nature Med. 1998; 4: 92–96
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Ring B. J., Watkins P. B., VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P450III family. Molec. Pharmacol. 1989; 36: 97–105
   PubMed Web of Science ®Google Scholar
• Schuetz J. D., Molowa D. T., Guzelian P. S. Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. Arch. Biochem. Biophys. 1989; 274: 355–365
   PubMed Web of Science ®Google Scholar
• Jounaidi Y, Hyrailles V, Gervot L, Maurel P. Detection of a CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein?. Biochem. Biophys. Res. Commun. 1996; 221: 466–470
   PubMed Web of Science ®Google Scholar
• Schuetz J. D., Schuetz E. G., Thottassery J. V., Guzelian P. S., Strom S, Sun D. Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Molec. Pharmacol. 1996; 49: 63–72
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Brian W. R., Sari M. A., Iwasaki M, Guengerich F. P., Raucy J. L., Molowa D. T., VandenBranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450 IIIA. Molec. Pharmacol. 1990; 38: 207–213
   PubMed Web of Science ®Google Scholar
• Gorski J. C., Hall S. D., Jones D. R., VandenBranden M, Wrighton S. A. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A subfamily. Biochem. Pharmacol. 1994; 47: 1643–1653
   PubMed Web of Science ®Google Scholar
• Kitada M, Kamataki T. Cytochrome P450 in human fetal liver: Significance and fetal-specific expression. Drug Metab. Rev. 1994; 26: 305–323
   PubMed Web of Science ®Google Scholar
• Kitada K, Kamataki T, Itahashi K, Rikihisa T, Kato R. Y. Kanakubo, Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Arch. Biochem. Biophys. 1985; 241: 275–280
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., VandenBranden M. Isolation and characterization of human fetal liver cytochrome P450HLp2: A third member of the P450III gene family. Arch. Biochem. Biophys. 1989; 268: 144–151
   PubMed Web of Science ®Google Scholar
• Kitada K, Taneda M, Itahashi K, Kamataki T. Four forms of cytochrome P-450 in human fetal liver: Purification and their capacity of activate promutagens. Jpn. J. Cancer Res. 1991; 82: 426–432
   PubMedGoogle Scholar
• Komori M, Nishio K, Ohi H, Kitada M, Kamataki T. Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450. J. Biochem. 1989; 105: 161–163
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Molowa D. T., Guzelian P. S. Identification of a cytochrome P-450 in human fetal liver related to glucocorticoid-inducible cytochrome P450HLp in the adult. Biochem. Pharmacol. 1988; 37: 3053–3055
   PubMed Web of Science ®Google Scholar
• Kitada M, Kamataki T, Itahashi K, Rikihisa T, Kanakubo Y. P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. J. Biol. Chem. 1987; 262: 13,534–13,537
   Google Scholar
• Burger H-J., Schuetz J. D., Schuetz E. G., Guzelian P. S. Paradoxical transcriptional activation of rat liver cytochrome P450 3A1 by dexamethasone and the antiglucocorticoid pregnenolone 16 alpha-carbonitrile: Analysis by transient transfection into primary monolayer cultures of adult rat hepatocytes. Proc. Natl. Acad. Sci. USA 1992; 89: 2145–2149
   PubMed Web of Science ®Google Scholar
• Hus J. M., Wang S. I., Astrom A, McQuiddy P, Kasper C. B. Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif. Proc. Natl. Acad. Sci. USA 1996; 93: 4666–4670
   PubMed Web of Science ®Google Scholar
• Lehmann J. M., McKee D. D., Watson M. A., Wilson T. M., Moore J. T., Kliewer S. A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 1998; 102: 1–8
   PubMedGoogle Scholar
• Blumberg B, Sabbagh W, Juguilon H, Bolado J, van Matel C. M. SXR, a novel steroid and xenobiotic sensing nuclear receptor. Genes Dev. 1998; 12: 3195–3205
   PubMed Web of Science ®Google Scholar
• Bertilsson G, Heidrich J, Svensson K. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. USA 1998; 95: 12,208–12,213
   Google Scholar
• Schuetz E. G., Brimer C, Schuetz J. D. Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone utilize the nuclear hormone receptor PXR to activate the cytochrome P4503A23 hormone response element. Molec. Pharm. 1998; 54: 1113–1117
   PubMed Web of Science ®Google Scholar
• Pascussi J-M., Jounaidi Y, Drocourt L, Domergu J, Balakaud C, Maurel P, Vileram M. J. Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem. Biophys. Res. Commun. 1999; 260: 377–381
   PubMed Web of Science ®Google Scholar
• Mangelsdorf D. J., Evans R. M. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841–850
   PubMed Web of Science ®Google Scholar
• Schmiedlin-Ren P, Thummel K. E., Fisher J. M., Paine M. F., Lown K. S., Watkins P. B. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1,2,5-dihydroxyvitamin D3. Molec. Pharm. 1997; 51: 741–754
   PubMed Web of Science ®Google Scholar
• Waxman D. J. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 1999; 369: 11–23
   PubMed Web of Science ®Google Scholar
• Savas U, Griffin K. J., Johnson E. F. Moleclar mechanisms of cytochrome P-450 induction by xenobiotics: An expanded role for nuclear hormone receptors. Molec. Pharm. 1999; 56: 851–857
   PubMed Web of Science ®Google Scholar
• Schuetz E. G., Schmid W, Schutz G. The glucocorticoid receptor is essential for induction of Cytochrome P4502B by steroids by not for drug or steroid induction of CYP3A or P450 reductase in mouse liver. Drug Metab., Dispos. 2000; 28: 268–278
   PubMed Web of Science ®Google Scholar
• Rebbeck T. R., Jaffe J. A., Walker A. H., Wein A. J., Malkowicz S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 1998; 90: 1225–1229
   PubMed Web of Science ®Google Scholar
• Hashimoto H., Toide K., Kitamura R., Fugita M., Tagawa S., Itoh S., Kamataki T. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur. J. Biochem. 1993; 218: 585–595
   PubMedGoogle Scholar
• Felix C. A., Walker A. H., Lange B. J. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA 1998; 95: 13, 176–13, 181
   Google Scholar
• Westlind A., Lofberg L., Tindberg N., Andersson T. B., Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun. 1999; 259: 201–205
   PubMed Web of Science ®Google Scholar
• Ball S. E., Scatina J., Kao J. Population distribution and effects on drug metabolism of a genetic variant in the 5′promoter region of CYP3A4. Clin. Pharmacol. Ther. 1999; 66: 288–294
   PubMed Web of Science ®Google Scholar
• Kralli A., Bohen S. P., Yamamoto K. R. LEM1, an ATP-binding-cassette transporter, selectively modulates the biological potency of steroid hormones. Proc. Natl. Acad. Sci. USA 1995; 92: 4701–4705
   PubMed Web of Science ®Google Scholar
• Barnes K. M., Dickstein B., Cutler G. B., Fojo T., Bates S. E. Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996; 35: 4820–4827
   PubMed Web of Science ®Google Scholar
• Meijer O. C., de Lange E. C. M., Breimer D. D., de Boer A. G., Workel J. O., de Kloet E. R. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1a P-glycoprotein knockout mice. Endocrinology 1998; 139: 1789–1793
   PubMed Web of Science ®Google Scholar
• Schuetz E. G., Beck W. T., Schuetz J. D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Molec. Pharm. 1996; 49: 311–318
   PubMed Web of Science ®Google Scholar
• Schuetz E. G., Schinkel A. H., Relling M. V., Schuetz J. D. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA 1996; 93: 4001–4005
   PubMed Web of Science ®Google Scholar
• Thummel K. E., Wilkinson G. R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 1998; 38: 389–430
   PubMed Web of Science ®Google Scholar
• Korzekwa K. R., Krishnamachary N., Shou M., Ogai A, Parise R. A., Rettie A. E., Gonzalez F. J., Tracy T. S. Evaluation of atypical cytochrome P450 kinetics with two-substrate-models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998; 37: 4137–4147
   PubMed Web of Science ®Google Scholar
• Watkins P. B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171–184
   PubMedGoogle Scholar
• Cheng C.-L., Smith D. E., Carver P. L., Cox S. R., Watkins P. B., Blake D. S., Kauffman C. A., Meyer K. M., Amidon G. L., Stetson P. L. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test. Clin. Pharmacol. Ther. 1997; 61: 531–543
   PubMed Web of Science ®Google Scholar
• Jamis-Dow C. A., Pearl M. L., Watkins P. B., Blake D. S., Klecker R. W., Collins J. M. Predicting drug interactions in vivo from experiments in vitro. Hu-jyman studies with paclitaxel and ketoconazole. Am. J. Clin. Oncol. 1997; 20: 592–599
   PubMed Web of Science ®Google Scholar
• Paine M. F., Shen D. D., Kunze K. L., Perkins J. D., Marsh C. L., McVicar J. P., Barr D. M., Gillies B. S., Thummel K. E. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 1996; 60: 14–24
   PubMed Web of Science ®Google Scholar
• Paine M. F., Khalighi M, Fisher J. M., Shen D. D., Kunze K. L., Marsh C. L., Perkins J. D., Thummel K. E. Characterization of inter- and intra-intestinal differences in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 1997; 283: 1552–1562
   PubMed Web of Science ®Google Scholar
• Rowland M, Matin S. B. Kinetics of drug–drug interactions. J. Pharmacokinet. Biopharm. 1973; 1: 553–567
   Google Scholar
• Gibbs M. A., Thummel K. E., Shen D. D., Kunze K. L. Inhibition of CYP3A in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos. 1999; 27: 180–187
   PubMed Web of Science ®Google Scholar
• Moltke L. L. v., Greenblatt D. J., Schmider J, Duan S. X., Wright C. E., Harmatz J. S., Shader R. I. Midazolam hydroxylation by liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol. 1996; 36: 783–791
   PubMed Web of Science ®Google Scholar
• Jurima-Romet M., Crawford K., Cyr T., Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab. Dispos. 1994; 22: 849–857
   PubMed Web of Science ®Google Scholar
• Iatsimirskaia E., Tulebaev S., Storozhuk E., Utkin I., Smith D., Gerber N., Koudriakova T. Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin. Pharmacol. Ther. 1997; 61: 554–562
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Ring B. J. Inhibition of human CYP3A catalyzed 1′-hydroxymidazolam formation by ketoconzole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm. Res. 1994; 11: 921–923
   PubMed Web of Science ®Google Scholar
• Olkkola K. T., Ahonen J, Neuvonen P. J. The effect of systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesthes. Analges. 1996; 82: 511–516
   PubMed Web of Science ®Google Scholar
• Olkkola K. T., Backman J. T., Neuvonen P. J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 1994; 55: 481–485
   PubMed Web of Science ®Google Scholar
• Backman J. T., Olkkola K. T., Aranko K, Himberg J.-J., Neuvonen P. J. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br. J. Clin. Pharmacol. 1994; 37: 221–225
   PubMed Web of Science ®Google Scholar
• Olkkola K. T., Aranko K, Luuila H, Hiller A, Saarnivaara L, Himberg J.-J., Neuvonen P. J. A potentially hazardous interaction between erythromycin and midazolam. Clin. Pharmacol. Ther. 1993; 53: 298–305
   PubMed Web of Science ®Google Scholar
• Gorski J. C., Jones D. R., Haehner-Daniels B. D., Hamman M. A., O'Mara E. M., Hall S. D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 1998; 64: 133–143
   PubMed Web of Science ®Google Scholar
• Lindstrom T. D., Hanssen B. R., Wrighton S. A. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rats and human livers. Antimicrob. Agent Chemother. 1993; 37: 265–269
   PubMed Web of Science ®Google Scholar
• Ohmori S, Ishii I, Kuriya S. I., Taniguchi T, Rikihisa T, Hirose S, Kanakubo Y, Kitada M. Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab. Dispos. 1993; 21: 358–363
   PubMed Web of Science ®Google Scholar
• Bartkowski R. R., Goldberg M. E., Larijani G. E., Boerner T. Inhibition of alfentanil metabolism by erythromycin. Clin. Pharmacol. Ther. 1989; 46: 99–102
   PubMed Web of Science ®Google Scholar
• Kharasch E. D., Russell M., Mautz D, Thummel K. E., Kunze K. L., Bowdle A. T., Cox K. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997; 87: 36–50
   PubMed Web of Science ®Google Scholar
• Wright C. E., Lasher-Sisson T. A., Steenwyk R. C., Swanson C. N. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992; 12: 103–106
   PubMed Web of Science ®Google Scholar
• Bergstrom R. F., Goldberg M. J., Cerimele B. J., Hatcher B. L. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin. Pharmacol. Ther. 1997; 62: 643–651
   PubMed Web of Science ®Google Scholar
• Jones J. P., Korzekwa K. R., Rettie A. E., Trager W. F. Isotopically sensitive branching and its effect on the observed intramolecular isotope effects in cytochrome P-450 catalyzed reactions: A new method for the estimation of intrinsic isotope effects. J. Am. Chem. Soc. 1986; 108: 7074–7078
   Web of Science ®Google Scholar
• Korzekwa K. R., Trager W. F., Gillette J. R. Theory for the observed isotope effects from enzymatic systems that form multiple products via branched reaction pathways: Cytochrome P-450. Biochemistry 1989; 28: 9012–9018
   PubMed Web of Science ®Google Scholar
• Iyer K. R., Jones J. P., Darbyshire J. F., Trager W. F. Intramolecular isotope effects for benzylic hydroxylation of isomeric xylenes and 4,4′-dimethylbiphenyl by cytochrome P450: Relationship between distance of methyl groups and masking of the intrinsic isotope effect. Biochemistry 1997; 36: 7136–7143
   PubMed Web of Science ®Google Scholar
• Korzekwa K. R., Trager W. F., Gillette J. R. Isotope effects studies on the cytochrome P450 enzymes. Drug Metab. Rev. 1995; 27: 45–59
   PubMed Web of Science ®Google Scholar
• Foster A. B. Deuterium isotope effects in the metabolism of drugs and xenobiotics: Implications for drug design. Adv. Drug Res. 1985; 14: 1–40
   Google Scholar
• Hanzlik R. P., Ling K.-H. J. Active site dynamics of toluene hydroxylation by cytochrome P450. J. Org. Chem. 1990; 55: 3392–3397
   Google Scholar
• Korzekwa K, Nagata K, Trager W. F., Gillette J. R. Metabolism of the B-ring of testosterone by the rat cytochrome P-450 system. Drug Metab. Rev. 1989; 20: 535–539
   PubMed Web of Science ®Google Scholar
• Korzekwa K. R., Jones J. P., Gillette J. R. Theoretical studies on cytochrome P-450 mediated hydroxylation: A predictive model for hydrogen atom abstractions. J. Am. Chem. Soc. 1990; 112: 7042–7046
   Web of Science ®Google Scholar
• Korzekwa K. R., Grogan J, DeVito S, Jones J. P. Electronic models for cytochrome P450 oxidations. Adv. Exp. Med. Biol. 1996; 387: 361–369
   PubMedGoogle Scholar
• Shou M., Grogan J., Mancewicz J. A., Krausz K. W., Gonzalez F. J., Gelboin H. V., Korzekwa K. R. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33: 6450–6455
   PubMed Web of Science ®Google Scholar
• Schwab G. E., Raucy J. L., Johnson E. F. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Molec. Pharmacol. 1988; 33: 493–499
   PubMed Web of Science ®Google Scholar
• Ueng Y.-F., Kuwabara T, Chun Y.-J., Guengerich F. P. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997; 36: 370–381
   PubMed Web of Science ®Google Scholar
• Kenworthy K. E., Bloomer J. C., Clarke S. E., Houston J. B. CYP3A4 drug interactions: Correlation of 10 in vitro prove substrates. Br. J. Clin. Pharmacol. 1999; 48: 716–727
   PubMed Web of Science ®Google Scholar
• Koley A. P., Robinson R. C., Friedman F. K. Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics. Biochimie 1996; 78: 706–713
   PubMed Web of Science ®Google Scholar
• Milewich L, Chen G. T., MacDonald P. C., Peterson J. A. Ascorbic acid inhibition of aromatase activity in human placenta tissue. J. Steroid Biochem. 1981; 14: 185–193
   PubMedGoogle Scholar
• Koley A. P., Buters J. T. M., Robinson R. C., Markowitz A, Friedman F. K. Differential mechanisms of cytochrome P450 inhibition and activation by alpha-naphthoflavone. J. Biol. Chem. 1997; 272: 3149–3152
   PubMed Web of Science ®Google Scholar
• Haehner B, Wrighton S. A., Janardan S. K., Watkins P. B., Hall S. A. Expression of CYP3A enzymes in human kidney. Molec. Pharmacol. 1996; 50: 52–59
   PubMed Web of Science ®Google Scholar
• Gosh S. S., Basu A. K., Gosh S, Hagley R, Kramer L, Schuetz J, Grogan W. M., Guzelian P. S., Watlington C. O. Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats. Biochem. Pharmacol. 1995; 50: 49–54
   PubMed Web of Science ®Google Scholar
• Clore J, Schoolwerth A, Watlington C. O. When is cortisol a mineralocorticoid? [editorial]. Kidney Int. 1992; 42: 1297–1308
   PubMed Web of Science ®Google Scholar
• Kolars J. C., Schmiedlin-Ren P., Schuetz J. D., Fang C., Watkins P. B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 1992; 90: 1871–1878
   PubMed Web of Science ®Google Scholar
• Brown M. B., Guo W., Watkins P. B. Grapefruit juice increases felodipine oral availability in man by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 1997; 99: 2545–2553
   PubMed Web of Science ®Google Scholar
• Schmiedlin-Ren P., Edwards D. J., Fitzsimmons M. E. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 1997; 25: 1228–1233
   PubMed Web of Science ®Google Scholar
• Hall S. D., Thummel K. E., Watkins P. B., Lown K. S., Benet L. Z., Paine M. F., Mayo R. R., Turgeon K., Bailey D. G., Fontana R. J., Wrighton S. A. Molecular and physical mechanisms of first-pass extraction. Drug Metab. Dispos. 1999; 27: 161–166
   PubMedGoogle Scholar
• Soldner A., Christians U., Susanto M., Wacher V. J., Silverman J. A., Benet L. Z. Grapefruit juice activates p-glycoprotein-mediated drug transport. Pharm. Res. 1999; 16: 4768–4785
   Google Scholar
• Edwards D., Fitzsimmons M. E., Schuetz E. G., Yasuda K., Ducharme M. P., Warbasse L. H., Woster P. M. J. D. Schuetz, and P. B. Watkins, 6,7-dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4 and P-glycoprotein. Clin. Pharmacol. Ther. 1999; 65: 237–244
   PubMed Web of Science ®Google Scholar